A lifelong transcatheter aortic valve prosthesis
One of 2,321 projects Taiyo tracks in Switzerland.
Source: EU Funding & Tenders Portal
Transcatheter aortic valve implantation (TAVI) techniques have revolutionized the therapy options for valvular heart disease. Initially developed for elderly high-risk patients, TAVI is being extended to younger patients and may become a first-line treatment in the near future. However, the available bioprostheses for TAVI are prone to degeneration, and patients may thus require multiple re-inter
- Status
- Under Construction
- Sector
- Education
- Location
- Switzerland
- Updated
- 22 Jul 2026
- Source
- EU Funding & Tenders Portal
ConstructChat
Ask ConstructChat about A lifelong transcatheter aortic valve prosthesis
Pick a question to edit it, or write your own.
First answer free · no account
Project Information FAQ
Project Information
Participants
| Not available for this record. |
Status
Original status | ongoing |
Taiyo status | Under Construction |
Taiyo last update | 2026-07-22 |
Contact
| Not available for this record. |
Description
Description | Transcatheter aortic valve implantation (TAVI) techniques have revolutionized the therapy options for valvular heart disease. Initially developed for elderly high-risk patients, TAVI is being extended to younger patients and may become a first-line treatment in the near future. However, the available bioprostheses for TAVI are prone to degeneration, and patients may thus require multiple re-interventions, significantly affecting their life quality. To date, a native-analogous TAVI prosthesis with in-situ remodeling capacity does not exist. Tissue engineered (TE) heart valves represent a potential solution, but are not yet suitable for high-pressure applications and lack clinical translation because of uncontrolled in-vivo remodeling, impairing their long-term functionality. In the TAVI4Life project, I aim to develop and validate a novel TAVI prosthesis for young patients with the unique ability to transform into a fully autologous valve within the body and last for life. This project will go far beyond previous TE concepts by engineering a novel decellularized human ECM and a bioresorbable stent and applying an unconventional bioengineering approach combining in-vitro, in-silico, and in-vivo TE methods. First, I will engineer and characterize a clinical-grade ECM for high-pressure conditions and test patient-specific immuno- and hemocompatibility profile (in-vitro). Next, using computational modeling, I will design and develop a bioresorbable stent and implement an analytical valve design to develop the transcatheter prosthesis (in-silico). Finally, I will evaluate valve performance and remodeling in a preclinical large animal model (in-vivo). This highly multidisciplinary approach will lead to a valve prosthesis that lasts for life, as guided in-situ tissue remodeling will enable their long-term performance. The clinical impact will be enormous as, particularly for young patients, the TAVI4Life will significantly enhance their life expectancy and quality of life. |
Location
Country | Switzerland |
Source
Source | EU Funding & Tenders Portal |
URL |
More Details
Record type | Project |
Sector | Education |
Article published date | 2026-02-01 |
Research
Free account
View all details
You are reading the public part. A free account opens the rest:
- Every detail on this project
- News and media coverage
- Technical research
Free account · no card · lands you back on this project
